ERS Genomics provides comment on EPO Technical Board of Appeal decision upholding the revocation of Broad Institute CRISPR patent  

Posted on by zymecom

DUBLIN, Ireland, 17 January 2020: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier, announced that yesterday the European Patent Office’s (EPO) Technical Board of Appeal (Board) upheld the earlier EPO Opposition Division ruling that the Broad Institute patent EP2771468 is not formally entitled to a number of its asserted priority dates and all its claims are therefore not novel and fully revoked.

 

EP2771468 is viewed as the Broad Institute’s foundational CRISPR-Cas9 patent in Europe. In January of 2018 the Opposition Division found that all claims of the Broad Institute’s patent were invalid because the Broad Institute was not entitled to its two earliest priority dates and thus the claims lacked novelty in light of prior art. The Broad Institute appealed the Opposition Division’s decision, which the Board affirmed yesterday. Thus, all claims of the Broad Institute’s patent remain fully revoked with no option left to overturn this decision.

 

“We are pleased to see that the EPO appeals board has upheld the earlier decision which resulted in the full revocation of this first significant patent,” commented Eric Rhodes, Chief Executive Officer, ERS Genomics,To have the issue resolved finally provides some measure of clarity to those companies interested in using and commercializing CRISPR/Cas9 technology. Today’s ruling significantly reduces Broad’s CRISPR/Cas9 patent footprint in Europe and should make licensing decisions much easier for those looking to utilize CRISPR/Cas9 technology in Europe.”

 

The Broad Institute obtained nine other patents that all suffer from the very same defect that resulted in the revocation of this first patent. Five of these nine patents have now been through the opposition process and three of them have been fully revoked by the Opposition Division while two were reduced to claim sets of no significance to the field. The Board’s decision reinforces the expectation that the remaining four patents still subject to opposition are likely to also be revoked or significantly reduced in claim scope.

 

For additional information please visit www.ersgenomics.com



This entry was posted in News from Zyme and the companies we work with. Bookmark the permalink.